Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
medmix AG ( (CH:MEDX) ) has shared an announcement.
medmix AG reported a 6.5% decline in revenue for the first half of 2025, attributed to subdued performance in the Beauty segment and foreign exchange impacts. Despite this, the company achieved increased profitability with an adjusted EBITDA margin of 19.9%, driven by strong growth in the Dental and Surgery segments and the implementation of a Growth and Efficiency program. The company has revised its revenue guidance for 2025 but confirmed its profitability targets, reflecting its strategic pivot towards high-margin healthcare businesses. The leadership team has been strengthened with new appointments, aiming to bolster the company’s focus on innovation and operational excellence.
The most recent analyst rating on (CH:MEDX) stock is a Buy with a CHF18.00 price target. To see the full list of analyst forecasts on medmix AG stock, see the CH:MEDX Stock Forecast page.
More about medmix AG
medmix AG operates in the healthcare and consumer & industrial sectors, focusing on products related to dental, surgery, drug delivery, and beauty. The company is committed to high growth and high margin healthcare businesses, with a strategic emphasis on efficiency and innovation.
Average Trading Volume: 53,056
Current Market Cap: CHF507.5M
Find detailed analytics on MEDX stock on TipRanks’ Stock Analysis page.